Patents

Patent granted for immunostimulatory DNA sequence molecule

Published in Cancer Weekly, August 5th, 2003

Dynavax Technologies announced that it has been granted U.S. Patent No. 6,589,940 B1 (the '940 patent), covering Dynavax's ISS (immunostimulatory DNA sequence) molecule known as "1018 ISS."

The first patent granted in the U.S. that claims an ISS alone as a composition of matter, the '940 patent gives Dynavax an important position in the rapidly developing field of ISS-based immunoregulatory agents. Dynavax employs the 1018 ISS molecule in four product candidates currently in clinical trials for allergy, asthma, hepatitis B, and cancer.

ISS are short synthetic DNA sequences containing a CpG dinucleotide that have been shown to act as signaling...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2003-08-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry